UPDATE 1-Allos gets EU orphan status for lymphoma drug

* Drug currently in early-stage trial

* Shares up 2 pct

June 17 (Reuters) - Allos Therapeutics Inc ALTH.O said its experimental cancer drug for cutaneous T-cell lymphoma (CTCL) received an orphan drug status from the European health regulators.

The designation from the European Commission may provide Allos up to 10-year market exclusivity in Europe, upon marketing approval of the drug pralatrexate.

The drug is currently in an early-stage trial in patients with relapsed or refractory CTCL, the company said in a statement.

CTCL is a rare type of non-Hodgkin’s lymphoma that can cause skin plaque and involve the blood and other organs.

Allos already has an orphan drug status for pralatrexate from the European Commission to treat a kind of blood cancer, peripheral T-Cell lymphoma and non-papillary transitional cell carcinoma of the urinary bladder, a form of bladder cancer.

Shares of Allos were up 2 percent at $6.82 in morning trade on Nasdaq. (Reporting by Shailesh Kuber in Bangalore; Editing by Vyas Mohan)